Comite Entreprise Paul Papin

15 Rue Andre Boquel, Angers, 49100, France

Medical Oncology – Non‑Small Cell Lung Cancer

The Comite Entreprise Paul Papin in Angers focuses on Neoplasms, specifically studying non‑small cell lung cancer (NSCLC) with both squamous and nonsquamous histology. Researchers are evaluating new treatment combinations to improve patient outcomes.

Overall survival comparison of novel therapy versus standard chemotherapy
Progression‑free survival assessment using blinded independent review
Evaluation of immunotherapy‑targeted agent synergy

With 76 investigators involved, the site’s patient‑centered approach aims to advance therapeutic options for advanced NSCLC after prior platinum‑based treatment.

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

Recruiting

2 1 1
Investigated diseases:
- Non-small cell lung cancer metastatic
- Neoplasm
Investigated drugs:
- VERT-002
Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

Recruiting

2 1 1 1
Investigated drugs:
- Durvalumab
Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer metastatic
- Non-small cell lung cancer
Investigated drugs:
- Pembrolizumab
+10
Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Recruiting

1 1 1 1
Investigated diseases:
- Prostate cancer metastatic
Investigated drugs:
+1
Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Recruiting

4 1 1 1
Investigated diseases:
- HER2 positive breast cancer
Investigated drugs:
+5
A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Recruiting

3 1 1 1
Investigated drugs:
- Bevacizumab
- Sacituzumab Tirumotecan
+9
Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Recruiting

3 1 1 1
Investigated diseases:
- Hormone receptor positive HER2 negative breast cancer
Investigated drugs:
A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Recruiting

3 1 1 1
Investigated drugs:
+8
A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Recruiting

3 1 1
Investigated drugs:
- Abiraterone Acetate
- Saruparib
+5
Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Recruiting

3 1 1 1
Investigated drugs:
+3